Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10709062 | 0.79 | KMO (0.55) | STAT3GRM4KMO | |
| SCHEMBL3408002 | 0.78 | MAPK1 (0.46) | STAT3HPGDALDH1A1CHEK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11809182 | 0.78 | KMO (0.40) | MALT1STAT3ALDH1A1CHEK1SMN1; SMN2 | |
| SCHEMBL31224184 | 0.75 | ALDH1A1 (0.49) | TSHRSTAT3HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL29723873 | 0.74 | KMO (0.38) | MALT1STAT3CHEK1SMN1; SMN2NPC1 | |
| SCHEMBL24387194 | 0.74 | KMO (0.38) | MALT1STAT3CHEK1SMN1; SMN2NPC1 | |
| SCHEMBL17440116 | 0.73 | GABRA1 (0.47) | ALDH1A1SMN1; SMN2NPC1LMNAPDGFRB | |
| SCHEMBL6098142 | 0.70 | HTR3A (0.61) | — | |
| SCHEMBL16319054 | 0.70 | NPC1 (0.38) | TSHRHPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL30753282 | 0.70 | RAB9A (0.49) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | MALT1 4003/4885TSHR 197/4885STAT3 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.